Tags : Febrile Neutropenia

Sandoz’s Ziextenzo (pegfilgrastim) Receives EU Approval for Reduction in Duration

Vartika Singh November 27, 2018

Shots: The approval is based on non-inferiority data with the reference biologic (Neulasta) showing biosimilarity in terms of safety, efficacy and quality Ziextenzo is a long-lasting form of filgrastim indicated […]readmore

Biosimilars Regulatory

Coherus Biosciences’ Udenyca (Pegfilgrastim Biosimilar) Receives EU Marketing Approval for

Vartika Singh September 26, 2018

Shots: Udenyca’s (Pegfilgrastim biosimilar) EU approval is based on the data demonstrating its PK and PD, for reducing the chances of infection by febrile neutropenia This biosimilar is currently under […]readmore

Biosimilars Regulatory

Sandoz’s Biosimilar Pegfilgrastim Receives CHMP Approval for Febrile Neutropenia

Vartika Singh September 21, 2018

Shots: The CHMP approval is based on data demonstrating analytical, preclinical, and clinical information, confirming biosimilar pegfilgrastim as a reference medicine in febrile neutropenia in terms of safety, efficacy and […]readmore

Tags : Febrile Neutropenia

Sandoz’s Ziextenzo (pegfilgrastim) Receives EU Approval for Reduction in Duration

Coherus Biosciences’ Udenyca (Pegfilgrastim Biosimilar) Receives EU Marketing Approval for

Sandoz’s Biosimilar Pegfilgrastim Receives CHMP Approval for Febrile Neutropenia

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Febrile Neutropenia

Sandoz’s Ziextenzo (pegfilgrastim) Receives EU Approval for Reduction in Duration

Coherus Biosciences’ Udenyca (Pegfilgrastim Biosimilar) Receives EU Marketing Approval for

Sandoz’s Biosimilar Pegfilgrastim Receives CHMP Approval for Febrile Neutropenia

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company